Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00412581 | Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 29, 2016 | clinicaltrials |
| NCT02755233 | Ipilimumab-induced Lung Toxicity: Observational Study(Ipi-Lu-Tox) | completed | — | 71 | University of ZurichOTHER | 1 | Apr 28, 2016 | clinicaltrials |
| NCT00897312 | Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease | terminated | — | 7 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Apr 25, 2016 | clinicaltrials |
| NCT01556503 | Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis | completed | — | 24 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 25, 2016 | clinicaltrials |
| NCT00716495 | Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma | terminated | Phase 1 / Phase 2 | 5 | AGIRx Ltd.INDUSTRY | 1 | Apr 22, 2016 | clinicaltrials |
| NCT02065466 | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | withdrawn | Phase 1 / Phase 2 | 0 | University of ArizonaOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02202200 | Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma(OPTIMUM) | unknown | Phase 1 / Phase 2 | 40 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT00613509 | Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma | terminated | Phase 2 | 23 | Sanofi Pasteur, a Sanofi CompanyINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT02671513 | A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients | unknown | Phase 1 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 12, 2016 | clinicaltrials |
| NCT01425749 | Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI(Mel55) | completed | Early Phase 1 | 25 | Craig L Slingluff, JrOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00004104 | Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02088762 | Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm) | completed | — | 325 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01744860 | Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples | completed | — | 420 | Hoffmann-La RocheINDUSTRY | 1 | Mar 28, 2016 | clinicaltrials |
| NCT00026221 | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00936221 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | completed | Phase 2 | 385 | AstraZenecaINDUSTRY | 12 | Mar 14, 2016 | clinicaltrials |
| NCT01990859 | Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients | completed | Phase 2 | 20 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT01700114 | Post-Approval Study of MelaFind | terminated | — | 487 | MELA Sciences, Inc.INDUSTRY | 1 | Mar 11, 2016 | clinicaltrials |
| NCT01730157 | Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases | terminated | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02129049 | Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children | completed | N/A | 35 | University of WashingtonOTHER | 1 | Mar 9, 2016 | clinicaltrials |
| NCT02147951 | Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma | no longer available | — | — | AmgenINDUSTRY | 1 | Mar 1, 2016 | clinicaltrials |
| NCT01665183 | Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma | completed | Phase 1 | 8 | Polaris GroupINDUSTRY | 2 | Feb 25, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01455259 | Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Uppsala UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00738361 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery | completed | Phase 2 | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT01200342 | Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00588341 | Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection | completed | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2016 | clinicaltrials |
| NCT01565837 | Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma(SART) | unknown | Phase 2 | 50 | Wolfram SamlowskiOTHER | 1 | Feb 1, 2016 | clinicaltrials |
| NCT02452281 | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Rabih SaidOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT02662725 | Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases(IPI+RTS) | completed | Phase 2 | 73 | University Hospital, LilleOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01435369 | Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma | completed | Phase 2 | 103 | Medivation, Inc.INDUSTRY | 2 | Jan 21, 2016 | clinicaltrials |
| NCT01621295 | Assessing the Patient Experience in Cancer Care | completed | — | 408 | Mayo ClinicOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT01983124 | Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib(BeyPro1) | completed | Phase 2 | 31 | Paola QueiroloOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00673361 | Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma | terminated | Phase 2 | 9 | Duke UniversityOTHER | 0 | Jan 13, 2016 | clinicaltrials |
| NCT00462982 | Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma | completed | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00568451 | Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT01028222 | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation(TEAM) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 30, 2015 | clinicaltrials |
| NCT00574977 | Safety Study of Modified Vaccinia Virus to Cancer | completed | Phase 1 | 26 | David BartlettOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT02224768 | YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey | completed | — | 158 | Bristol-Myers SquibbINDUSTRY | 2 | Dec 21, 2015 | clinicaltrials |
| NCT00289016 | A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma | completed | Phase 2 | 50 | BioVex LimitedINDUSTRY | 2 | Dec 18, 2015 | clinicaltrials |
| NCT00574392 | Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo | completed | — | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2015 | clinicaltrials |
| NCT01368276 | An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma | completed | Phase 3 | 31 | BioVex LimitedINDUSTRY | 2 | Dec 18, 2015 | clinicaltrials |
| NCT02574260 | An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) | completed | Phase 2 | 3 | BioVex LimitedINDUSTRY | 0 | Dec 17, 2015 | clinicaltrials |
| NCT00006022 | Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer | completed | Phase 1 | 17 | Virginia Commonwealth UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT00185302 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma | completed | Phase 2 | 28 | BayerINDUSTRY | 0 | Dec 14, 2015 | clinicaltrials |
| NCT02357732 | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | withdrawn | Phase 1 | 0 | University of PittsburghOTHER | 0 | Dec 11, 2015 | clinicaltrials |
| NCT02619058 | A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients | unknown | Phase 1 | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00003715 | Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | terminated | Phase 2 | 425 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00257465 | Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma | completed | Phase 1 / Phase 2 | 82 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00477906 | M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma | unknown | Phase 3 | 387 | AVAX TechnologiesINDUSTRY | 0 | Dec 3, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Apr 29, 2016source: clinicaltrials